<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871858</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000633329</org_study_id>
    <secondary_id>2007-004216-31</secondary_id>
    <nct_id>NCT00871858</nct_id>
  </id_info>
  <brief_title>Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer</brief_title>
  <acronym>HORGEN</acronym>
  <official_title>Response to Neoadjuvant Treatment With Anti-aromatase Anastrozole and Anti-estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-sensitive Non-metastatic Breast Cancer and an Exploratory Study of Molecular Signatures of Response.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using&#xD;
      anastrozole may fight breast cancer by lowering the amount of estrogen the body makes.&#xD;
      Fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. Given&#xD;
      the lack of clinical data on fulvestrant in patients with large operable or locally advanced&#xD;
      hormone-receptor-positive breast cancer, and the potential to identify differences in the&#xD;
      mechanism of resistance using the neoadjuvant model,we decided to perform a multicentre&#xD;
      randomised phase II clinical trial of anastrozole and fulvestrant.&#xD;
&#xD;
      PURPOSE: The aim of this study was to assess the efficacy of neoadjuvant anastrozole and&#xD;
      fulvestrant treatment of large operable or locally advanced hormone-receptor-positive breast&#xD;
      cancer not eligible for initial breast-conserving surgery, and to identify genomic changes&#xD;
      occurring after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate clinical tumor response at 6 months in patients with hormone-sensitive&#xD;
           non-metastatic breast cancer treated with neoadjuvant anastrozole and fulvestrant.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate tumor regression by mammography and ultrasound in these patients.&#xD;
&#xD;
        -  Evaluate the rate of breast conservation at 6 months of treatment in these patients.&#xD;
&#xD;
        -  Evaluate the tolerability of these regimens.&#xD;
&#xD;
        -  Estimate the relapse-free survival at 5 years.&#xD;
&#xD;
        -  Identify molecular signatures predictive of response in these patients.&#xD;
&#xD;
        -  Identify genes implicated in response in these patients.&#xD;
&#xD;
        -  Identify changes in mRNA splicing of genes involved in breast tumorigenesis.&#xD;
&#xD;
      OUTLINE: This is a non-comparative multicentre randomised phase II study in which patients&#xD;
      from three French centres were randomly assigned in a 1 : 1 ratio to receive either&#xD;
      anatrozole or fulvestrant.&#xD;
&#xD;
      All patients undergo biopsy at baseline. Patients are randomized between the two treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral anastrozole once daily for 6 months.&#xD;
&#xD;
        -  Arm II: Patients receive fulvestrant intramuscularly on days 1, 14, and 28 and then once&#xD;
           a month at 2-6 months.&#xD;
&#xD;
      Within 8 days after completion of hormone therapy, all patients undergo surgical resection of&#xD;
      the residual lesion followed by radiotherapy. Patients then receive oral anastrozole once&#xD;
      daily for 5 years.&#xD;
&#xD;
      Tissue samples from biopsy and surgery are analyzed to assess molecular signatures and&#xD;
      sensitivity to treatment, and to compare gene expression variation with response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2008</start_date>
  <completion_date type="Actual">July 2, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) Determined by Clinical Palpation</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.&#xD;
Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Determined by Ultrasound</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.&#xD;
Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Determined by Mammography</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.&#xD;
Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Breast-conserving Surgery</measure>
    <time_frame>6 months</time_frame>
    <description>breast-conserving surgery concerns patients who did not undergo mastectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With 5-year Relapse-Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Relapse-Free survival (RFS) is measured from the date of randomization to the date of the following events, whichever occurs first according to the DATECAN recommendations for breast cancer:&#xD;
Invasive ipsilateral breast tumor recurrence/ progression ;&#xD;
Local invasive recurrence/progression ;&#xD;
Regional invasive recurrence/progression (N+: regional progression) ;&#xD;
Appearance/Occurrence of Metastatic recurrence;&#xD;
Death whatever the cause.&#xD;
Participants who did not experience events were censored at the date of last follow-up. RFS was estimated using the Kaplan-Meier method. No comparison test was performed between the two arms as this study is non-comparative.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (ANA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (FULV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm A (ANA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>Given intramuscularly</description>
    <arm_group_label>Arm B (FULV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer, meeting 1 of the following criteria:&#xD;
&#xD;
               -  SBR grade I-II disease (patients &lt; 65 years of age)&#xD;
&#xD;
               -  SBR grade I-III disease (patients &gt; 65 years of age)&#xD;
&#xD;
          -  T2 (2-5 cm), T3, or T4B, and N0-1 disease&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
          -  Breast lesion not amenable to breast-conserving resection&#xD;
&#xD;
          -  No inflammatory breast cancer&#xD;
&#xD;
          -  No prior breast cancer&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor- and/or progesterone receptor-positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
          -  No other cancer within the past 5 years except for adequately treated skin carcinoma&#xD;
             or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No contraindication to anti-hormonal treatment&#xD;
&#xD;
          -  No psychological, familial, social, or geographical reasons that would preclude follow&#xD;
             up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 8 days since prior hormone replacement therapy&#xD;
&#xD;
          -  No concurrent anti-vitamin K treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis Mauriac, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Quenel-Tueux N, Debled M, Rudewicz J, MacGrogan G, Pulido M, Mauriac L, Dalenc F, Bachelot T, Lortal B, Breton-Callu C, Madranges N, de Lara CT, Fournier M, Bonnefoi H, Soueidan H, Nikolski M, Gros A, Daly C, Wood H, Rabbitts P, Iggo R. Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer. Br J Cancer. 2015 Aug 11;113(4):585-94. doi: 10.1038/bjc.2015.247. Epub 2015 Jul 14.</citation>
    <PMID>26171933</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <results_first_submitted>January 13, 2021</results_first_submitted>
  <results_first_submitted_qc>January 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>progesterone receptor-positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A (ANA)</title>
          <description>Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.&#xD;
anastrozole: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Arm B (FULV)</title>
          <description>Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.&#xD;
fulvestrant: Given intramuscularly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable for Safety</title>
              <participants_list>
                <participants group_id="P1" count="60">1 patient refused to continue study and therefore did not received treatment.</participants>
                <participants group_id="P2" count="58">1 patient refused to continue study after randomization and therefore did not received treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A (ANA)</title>
          <description>Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.&#xD;
anastrozole: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Arm B (FULV)</title>
          <description>Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.&#xD;
fulvestrant: Given intramuscularly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.1" lower_limit="64.1" upper_limit="77.5"/>
                    <measurement group_id="B2" value="70.5" lower_limit="64.0" upper_limit="77.8"/>
                    <measurement group_id="B3" value="69.8" lower_limit="64.0" upper_limit="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR) Determined by Clinical Palpation</title>
        <description>Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.&#xD;
Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (ANA)</title>
            <description>Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.&#xD;
anastrozole: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm B (FULV)</title>
            <description>Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.&#xD;
fulvestrant: Given intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) Determined by Clinical Palpation</title>
          <description>Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.&#xD;
Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" lower_limit="45.0" upper_limit="71.9"/>
                    <measurement group_id="O2" value="53.8" lower_limit="39.5" upper_limit="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) Determined by Ultrasound</title>
        <description>Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.&#xD;
Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).</description>
        <time_frame>6 months</time_frame>
        <population>Out of 108 patients (56 arm A + 52 arm B) evaluable for efficacy (&quot;completed&quot; in flow chart) : 19 patients in Arm A and 31 in arm B with missing size at ultrasound examination</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (ANA)</title>
            <description>Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.&#xD;
anastrozole: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm B (FULV)</title>
            <description>Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.&#xD;
fulvestrant: Given intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) Determined by Ultrasound</title>
          <description>Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.&#xD;
Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).</description>
          <population>Out of 108 patients (56 arm A + 52 arm B) evaluable for efficacy (&quot;completed&quot; in flow chart) : 19 patients in Arm A and 31 in arm B with missing size at ultrasound examination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" lower_limit="20.2" upper_limit="52.5"/>
                    <measurement group_id="O2" value="52.4" lower_limit="29.8" upper_limit="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) Determined by Mammography</title>
        <description>Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.&#xD;
Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).</description>
        <time_frame>6 months</time_frame>
        <population>Out of 108 patients (56 arm A + 52 arm B) evaluable for efficacy (&quot;completed&quot; in flow chart) : 33 patients in Arm A and 34 in arm B with missing size at mammography.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (ANA)</title>
            <description>Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.&#xD;
anastrozole: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm B (FULV)</title>
            <description>Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.&#xD;
fulvestrant: Given intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) Determined by Mammography</title>
          <description>Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.&#xD;
Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).</description>
          <population>Out of 108 patients (56 arm A + 52 arm B) evaluable for efficacy (&quot;completed&quot; in flow chart) : 33 patients in Arm A and 34 in arm B with missing size at mammography.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="10.4" upper_limit="48.4"/>
                    <measurement group_id="O2" value="27.8" lower_limit="9.7" upper_limit="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Breast-conserving Surgery</title>
        <description>breast-conserving surgery concerns patients who did not undergo mastectomy.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (ANA)</title>
            <description>Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.&#xD;
anastrozole: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm B (FULV)</title>
            <description>Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.&#xD;
fulvestrant: Given intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Breast-conserving Surgery</title>
          <description>breast-conserving surgery concerns patients who did not undergo mastectomy.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7" lower_limit="46.8" upper_limit="73.5"/>
                    <measurement group_id="O2" value="50.0" lower_limit="35.8" upper_limit="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With 5-year Relapse-Free Survival</title>
        <description>Relapse-Free survival (RFS) is measured from the date of randomization to the date of the following events, whichever occurs first according to the DATECAN recommendations for breast cancer:&#xD;
Invasive ipsilateral breast tumor recurrence/ progression ;&#xD;
Local invasive recurrence/progression ;&#xD;
Regional invasive recurrence/progression (N+: regional progression) ;&#xD;
Appearance/Occurrence of Metastatic recurrence;&#xD;
Death whatever the cause.&#xD;
Participants who did not experience events were censored at the date of last follow-up. RFS was estimated using the Kaplan-Meier method. No comparison test was performed between the two arms as this study is non-comparative.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (ANA)</title>
            <description>Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.&#xD;
anastrozole: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm B (FULV)</title>
            <description>Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.&#xD;
fulvestrant: Given intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 5-year Relapse-Free Survival</title>
          <description>Relapse-Free survival (RFS) is measured from the date of randomization to the date of the following events, whichever occurs first according to the DATECAN recommendations for breast cancer:&#xD;
Invasive ipsilateral breast tumor recurrence/ progression ;&#xD;
Local invasive recurrence/progression ;&#xD;
Regional invasive recurrence/progression (N+: regional progression) ;&#xD;
Appearance/Occurrence of Metastatic recurrence;&#xD;
Death whatever the cause.&#xD;
Participants who did not experience events were censored at the date of last follow-up. RFS was estimated using the Kaplan-Meier method. No comparison test was performed between the two arms as this study is non-comparative.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="69.6" upper_limit="90.7"/>
                    <measurement group_id="O2" value="74.7" lower_limit="60.4" upper_limit="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A (ANA)</title>
          <description>Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.&#xD;
anastrozole: Given orally</description>
        </group>
        <group group_id="E2">
          <title>Arm B (FULV)</title>
          <description>Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.&#xD;
fulvestrant: Given intramuscularly</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Clear cell kidney cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Programmed peritoneal dialysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>SOC CTCAE V3.0 = constitutional symptoms</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <description>SOC CTCAE V3.0= Dermatology/Skin</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <description>SOC CTCAE V3.0= Constitutional symptoms</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>SOC CTCAE V3.0=PAIN</description>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="60"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <description>SOC CTCAE V3.0= PAIN</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>SOC CTCAE V3.0= Neurology</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <description>SOC CTCAE V3.0=Neurology / AE term CTCAE V3.0= Mood alteration</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <description>SOC CTCAE V3.0=Endocrine gastrointestinal</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="60"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nathalie Quenel-Tueux</name_or_title>
      <organization>Institut Bergonié, Medical Oncology department</organization>
      <phone>05.56.33.33.33</phone>
      <email>N.Quenel-Tueux@bordeaux.unicancer.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

